Deregulated STAT3 activation has been reported in various human cancers including HCC and linked with the advancement of cancer, chemoresistance, poor clinical outcome, and decreased overall survival rate [21,22,23,24]. Here, STAT3 is linked to hepatocellular carcinoma.